10 Other operating income and expenses
|
millions of CHF |
|
2024 |
|
2023 |
|
Income from release of contingent consideration |
|
2.0 |
|
0.5 |
|
Gain from sale of property, plant and equipment |
|
1.2 |
|
0.6 |
|
Gain from deconsolidation of subsidiaries |
|
– |
|
8.3 |
|
Other operating income |
|
–0.0 |
|
8.3 |
|
Total other operating income |
|
3.2 |
|
17.7 |
|
|
|
|
|
|
|
Other operating expenses 1) |
|
0.0 |
|
–3.0 |
|
Impairments on tangible and intangible assets |
|
–0.0 |
|
–0.2 |
|
Cost for mergers and acquisitions |
|
–1.9 |
|
–1.8 |
|
Loss from sale of property, plant and equipment |
|
–0.9 |
|
–0.1 |
|
Loss from deconsolidation of subsidiaries |
|
–0.1 |
|
–1.1 |
|
Operating currency exchange losses, net |
|
–4.4 |
|
–2.3 |
|
Other operating expenses |
|
–1.9 |
|
–0.0 |
|
Total other operating expenses |
|
–9.2 |
|
–8.4 |
|
|
|
|
|
|
|
Total other operating income / (expenses), net |
|
–6.0 |
|
9.2 |
1) The line “other operating expenses” was presented as “restructuring expenses” in the 2023 financial statements. In 2024, restructuring expenses were presented in the income statement on the expense accounts of the respective function. See note 26 for details on restructuring expenses.
In 2024, other operating income includes CHF 1.2 million gain from sale of property, plant and equipment and CHF 2.0 million income from a partial release of a contingent consideration (see note 3).
In 2023, other operating income included income from charges to the discontinued operation Applicator Systems division (later renamed medmix) for corporate support functions and centrally procured indirect spend utilized by medmix of CHF 1.6 million.
In 2023, the total gain from deconsolidation primarily included a gain of CHF 8.0 million from the deconsolidation of four Russian legal entities. The total gain and loss from deconsolidation includes a net gain from the reclassification of currency translation adjustments of CHF 10.9 million and a gain of CHF 0.6 million from the reclassification of cash flow hedge reserves (see note 4).
In 2024, other operating expenses includes mainly expenses from litigation cases and other taxes.
In 2023, the group recognized net impairment losses on tangible and intangible assets amounting to CHF 0.2 million consisting of impairment losses of CHF 1.0 million, partially offset with the reversal of impairment losses amounting to CHF 0.8 million.
In 2023, the group recognized restructuring costs of CHF 5.2 million, partially offset with the release of restructuring provisions of CHF 2.2 million. Restructuring costs mainly related to resizing activities in Ireland and Australia.